Tradestie Institutional Equity Comparison Engine
NUVB vs RAPP โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
NUVB Overall Edge
NUVB Captures Institutional Edge (2โ1 Pillars ยท 4โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Nuvation Bio Inc. (NUVB) driven by superior Growth & Margin, Options & Structure while RAPP counters with relative strength in Momentum & Technical. Fundamentally, NUVB trades at N/M Forward P/E with -61.2% operating margin (+242.6% YoY revenue) versus RAPP at N/M Forward P/E and -838.1% operating margin (+0.0% YoY). In options structure, NUVB sits in BREAKDOWN (26th %ile IV; Dealer Gamma Walls on Pro) against RAPP sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
NUVB N/M vs RAPP N/M Fwd P/E
Growth & Margin Winner
NUVB
Op Margin -61.2% vs -838.1% ยท YoY +242.6% vs +0.0%
Momentum & Technical Winner
RAPP
1Y -46.9% vs -13.8% ยท 52W Pos 2% vs 4%
Options & Structure Winner
NUVB
BREAKDOWN (26th %ile IV) vs BREAKDOWN (8th %ile IV)
NUVB
NYSE
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap
$1.3B
1M Return
-19.15%
1Y Return
-46.85%
Forward P/E
N/M
Unified AI Score
61.0 / 100
BUY
Tech 53.0
Fund 61.0
Flow 67.0
Mom 64.0
RAPP
NASDAQ
Rapport Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$23.16
-1.82% 1D
Market Cap
$1.4B
1M Return
-12.7%
1Y Return
-13.84%
Forward P/E
N/M
Unified AI Score
50.9 / 100
HOLD
Tech 56.0
Fund 61.0
Flow 65.0
Mom 64.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
NUVB -46.85%
RAPP -13.84%
Spread: +33.01 pp (RAPP Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
NUVB TTM Op. Margin: -61.2%
RAPP TTM Op. Margin: -838.1%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NUVB vs RAPP. Trailing 12-month operating profitability (NUVB -61.2% vs RAPP -838.1%) and valuation multiples (NUVB N/M vs RAPP N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | NUVB | RAPP | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.3B | $1.4B | Larger Scale | RAPP |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +242.6% | +0.0% | Higher Growth | NUVB |
| Operating Margin (TTM) Profitability | -61.2% | -838.1% | Higher Margin | NUVB |
| Net Profit Margin Profitability | -67.4% | 0.0% | Higher Margin | RAPP |
| Return on Equity (ROE) Capital Efficiency | -49.1% | -33.3% | Higher ROE | RAPP |
| 52-Week Range Position Momentum | 2% ($4โ$10) | 4% ($22โ$53) | Stronger Trend | RAPP |
| Beta / 30D Volatility Risk Regime | 1.52ฮฒ ยท 55% Vol | 1.22ฮฒ ยท 92% Vol | Lower Realized Risk | NUVB |
| Unified Institutional Score Composite Signal | 61.0 / 100 (BUY) | 50.9 / 100 (HOLD) | Higher Composite | NUVB |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full NUVB vs RAPP Buy Guide
NUVB
BREAKDOWN
105d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
26th %ile
IV Regime
Balanced (25thโ60th %ile)
RAPP
BREAKDOWN
137d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
8th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither NUVB nor RAPP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.